A study has revealed that galloylquinic acids extracted from the leaves of Copaifera lucens Dwyer, a tree endemic to Brazil primarily found in the Atlantic Forest, have a multi-targeted effect against SARS-CoV-2, the virus that causes COVID-19.
Scientists have identified and characterized a new class of Streptomyces-produced toxins that are very distantly related to the deadly toxin that causes diphtheria, a serious and contagious infection, in humans.
A new study has found that pet cats allowed to roam outside unsupervised carry infectious diseases at rates comparable to feral cats, even when they receive veterinary care, regular meals and shelter.
A comprehensive investigation has identified a previously underappreciated source of thermotolerant Campylobacter spp. in South American camelids (SACs)—alpacas and llamas kept in Germany. The findings underscore the importance of expanding epidemiological surveillance beyond traditional livestock.
A new study has identified a significant rise in Valley fever cases in El Paso over the past decade and found strong connections between the disease and extreme weather, wind and airborne dust.
Researchers have made an important discovery that could help doctors tell Ebola apart from other infections more quickly. The overlap of response by Ebola and other pathogens had made it difficult to find markers that are truly unique to Ebola.
A study has revealed that galloylquinic acids extracted from the leaves of Copaifera lucens Dwyer, a tree endemic to Brazil primarily found in the Atlantic Forest, have a multi-targeted effect against SARS-CoV-2, the virus that causes COVID-19.
Scientists have identified and characterized a new class of Streptomyces-produced toxins that are very distantly related to the deadly toxin that causes diphtheria, a serious and contagious infection, in humans.
A new study has found that pet cats allowed to roam outside unsupervised carry infectious diseases at rates comparable to feral cats, even when they receive veterinary care, regular meals and shelter.
Scientists have developed new compounds against non-tuberculous mycobacteria which are now the subject of a new collaboration and license agreement with the Switzerland-based and publicly listed BioVersys AG.
The Vanderbilt Center for Antibody Therapeutics has signed an option agreement with Saravir Biopharma Inc. for the company to develop human monoclonal antibodies isolated in the laboratory of James Crowe Jr., MD, for the treatment and prevention of measles.
UK-BASED cleanroom engineering company Total Clean Air (TCA), a UKAS ISO 17025-accredited cleanroom constructor, has been appointed European partner for US-based decontamination technology firm TOMI®Environmental Solutions.
Anyone who has ever used a microscope knows that it takes time to bring a sample into sharp focus. Now a team of scientists has developed an inexpensive robust fix for this problem that involves little more than a couple of LED lights and some physics-based processing.
Scientists have developed an adhesive gel that can be loaded with substances, such as small molecule drugs or nanoparticles, and applied directly onto a plant to deliver those materials into its tissues. In tests, a gel loaded with antibiotics cleared a bacterial infection in a plant within about 48 hours.
A major collaboration involving nine labs has transferred a particularly useful DNA editing system from E. coli into 14 new species of bacteria, spanning three major branches of the bacterial family tree.
A new handbook has been published to pave the way for better decision-making and greater preparedness for the next pandemic. It provides practical guidance on how mathematical models can be used to inform decision-making, and how the results can be communicated in times of crisis.
The new vaccine momentum reflects the growing urgency of avian influenza (H5N1) threat and reinforces the need for coordinated global preparedness.
The Targeting Phage Therapy 2026 Congress will bring together leading scientists, clinicians, microbiologists, engineers, biotech leaders, regulators, hospital teams, start-ups, and innovators to ask: How can phage therapy move from promising science to accessible, validated, and deployable medicine?